{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:21:57Z","timestamp":1787840517618,"version":"build-2784847793"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"Abstract<\/jats:title>\n \n Purpose:<\/jats:title>\n To identify predictive factors for recurrence and to assess variables influencing visual acuity over time.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n This retrospective study analyzed 137 eyes of 128 patients with myopic choroidal neovascularization (mCNV) treated with intravitreal antivascular endothelial growth factor injections (ranibizumab or aflibercept) between June 2017 and June 2022, with a minimum 12-month follow-up. The study cohort was divided into two groups: The recurrence (R) group, which included eyes that experienced a recurrence of mCNV activity, and the nonrecurrence (NR) group, which included eyes without recurrence.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n The R group consisted of 56 eyes, whereas the NR group included 81 eyes. Recurrence was significantly associated with lower baseline best-corrected visual acuity (BCVA) (odds ratio [OR]: 1.95;\n P<\/jats:italic>\n = 0.018), higher central foveal thickness (OR: 0.922;\n P<\/jats:italic>\n = 0.001), presence of retinal pigment epithelium (RPE) disruption (OR: 2.272;\n P<\/jats:italic>\n = 0.022), presence of subretinal fluid (OR: 2.83;\n P<\/jats:italic>\n = 0.008), CNV width (OR: 1.1;\n P<\/jats:italic>\n = 0.041), and CNV height (OR: 1.3;\n P<\/jats:italic>\n = 0.045). In the NR group, final BCVA was significantly influenced by age (\n P<\/jats:italic>\n = 0.001), time to first injection (\n P<\/jats:italic>\n = 0.021), baseline BCVA (\n P<\/jats:italic>\n = 0.001), BCVA after initial therapy (\n P<\/jats:italic>\n = 0.001), RPE disruption (\n P<\/jats:italic>\n = 0.019), photoreceptor layer disruption (\n P<\/jats:italic>\n = 0.048), and lesion thickness (\n P<\/jats:italic>\n = 0.033). In the R group, 12-month BCVA correlated with baseline BCVA (\n P<\/jats:italic>\n = 0.0019), number of injections (\n P<\/jats:italic>\n = 0.08), RPE disruption (\n P<\/jats:italic>\n = 0.027), ellipsoid zone disruption (\n P<\/jats:italic>\n = 0.046), and CNV height (\n P<\/jats:italic>\n = 0.084).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Baseline clinical and imaging biomarkers are significantly associated with both recurrence risk and visual outcomes in mCNV. Early identification of these predictive factors may guide treatment strategies and optimize long-term visual prognosis.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/joco.joco_177_25","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:03:17Z","timestamp":1773824597000},"page":"339-345","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Retinal Predictors of Visual Outcome and Recurrence in Na\u00efve Myopic Choroidal Neovascularization Patients"],"prefix":"10.4103","volume":"37","author":[{"given":"Leandro","family":"Inferrera","sequence":"first","affiliation":[{"name":"Department of Medical, Surgical Sciences and Health, University of Trieste, Trieste, TS, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gaggino","sequence":"additional","affiliation":[{"name":"Department of Medical, Surgical Sciences and Health, University of Trieste, Trieste, TS, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Drigo","sequence":"additional","affiliation":[{"name":"Department of Medical, Surgical Sciences and Health, University of Trieste, Trieste, TS, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Agolini","sequence":"additional","affiliation":[{"name":"Department of Medical, Surgical Sciences and Health, University of Trieste, Trieste, TS, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Caltagirone","sequence":"additional","affiliation":[{"name":"Department of Medical, Surgical Sciences and Health, University of Trieste, Trieste, TS, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Verdimonti","sequence":"additional","affiliation":[{"name":"Department of Medical, Surgical Sciences and Health, University of Trieste, Trieste, TS, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Tognetto","sequence":"additional","affiliation":[{"name":"Department of Medical, Surgical Sciences and Health, University of Trieste, Trieste, TS, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"R1-20260319","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","article-title":"Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: An evidence-based systematic review","volume":"157","author":"Wong","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R2-20260319","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.preteyeres.2012.04.001","article-title":"Choroidal neovascularization in pathological myopia","volume":"31","author":"Neelam","year":"2012","journal-title":"Prog Retin Eye Res"},{"key":"R3-20260319","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1167\/iovs.18-24032","article-title":"Prevalence, risk factors, and impact of myopic macular degeneration on visual impairment and functioning among adults in Singapore","volume":"59","author":"Wong","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R4-20260319","doi-asserted-by":"crossref","first-page":"M20","DOI":"10.1167\/iovs.18-25957","article-title":"IMI \u2013Defining and classifying myopia: A proposed set of standards for clinical and epidemiologic studies","volume":"60","author":"Flitcroft","year":"2019","journal-title":"Investig Opthalmol Vis Sci"},{"key":"R5-20260319","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/IAE.0000000000001348","article-title":"What is the fundamental nature of pathologic myopia?","volume":"37","author":"Ohno-Matsui","year":"2017","journal-title":"Retina"},{"key":"R6-20260319","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.preteyeres.2018.10.005","article-title":"Myopic maculopathy: Current status and proposal for a new classification and grading system (ATN)","volume":"69","author":"Ruiz-Medrano","year":"2019","journal-title":"Prog Retin Eye Res"},{"key":"R7-20260319","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1136\/bjo.87.5.570","article-title":"Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia","volume":"87","author":"Ohno-Matsui","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"R8-20260319","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.preteyeres.2017.10.005","article-title":"Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia","volume":"63","author":"Ohno-Matsui","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"R9-20260319","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.ophtha.2017.04.028","article-title":"Myopic choroidal neovascularization","volume":"124","author":"Cheung","year":"2017","journal-title":"Ophthalmology"},{"key":"R10-20260319","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.survophthal.2021.06.005","article-title":"The cause of myopia development and progression: Theory, evidence, and treatment","volume":"67","author":"Medina","year":"2022","journal-title":"Surv Ophthalmol"},{"key":"R11-20260319","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.survophthal.2023.07.006","article-title":"Pathogenesis of myopic choroidal neovascularization: A systematic review and meta-analysis","volume":"68","author":"Zhang","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"R12-20260319","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.preteyeres.2015.12.001","article-title":"Updates of pathologic myopia","volume":"52","author":"Ohno-Matsui","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"R13-20260319","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","article-title":"RADIANCE: A randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia","volume":"121","author":"Wolf","year":"2014","journal-title":"Ophthalmology"},{"key":"R14-20260319","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00417-004-0960-5","article-title":"Characteristics of patients with a favorable natural course of myopic choroidal neovascularization","volume":"243","author":"Hayashi","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R15-20260319","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0161-6420(03)00461-5","article-title":"Myopic choroidal neovascularization: A 10-year follow-up","volume":"110","author":"Yoshida","year":"2003","journal-title":"Ophthalmology"},{"key":"R16-20260319","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s00417-003-0803-9","article-title":"Factors associated with the development of chorioretinal atrophy around choroidal neovascularization in pathologic myopia","volume":"242","author":"Kojima","year":"2004","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R17-20260319","doi-asserted-by":"crossref","first-page":"e001396","DOI":"10.1136\/bmjophth-2023-001396","article-title":"Recurrence risk of myopic choroidal neovascularisation: A systematic review of current study","volume":"8","author":"Victor","year":"2023","journal-title":"BMJ Open Ophthalmol"},{"key":"R18-20260319","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.ophtha.2013.06.010","article-title":"Ranibizumab in myopic choroidal neovascularization: The 12-month results from the REPAIR study","volume":"120","author":"Tufail","year":"2013","journal-title":"Ophthalmology"},{"key":"R19-20260319","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","article-title":"Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: The MYRROR Study","volume":"122","author":"Ikuno","year":"2015","journal-title":"Ophthalmology"},{"key":"R20-20260319","doi-asserted-by":"crossref","first-page":"e0271342","DOI":"10.1371\/journal.pone.0271342","article-title":"Incidence, predictors and re-treatment outcomes of recurrent myopic choroidal neo-vascularization","volume":"17","author":"Jain","year":"2022","journal-title":"PLoS One"},{"key":"R21-20260319","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1097\/IAE.0000000000001858","article-title":"Long-term outcomes of ranibizumab treatment of myopic choroidal neovascularization in East-Asian patients from the radiance study","volume":"38","author":"Tan","year":"2018","journal-title":"Retina"},{"key":"R22-20260319","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000458160","article-title":"Improved visual outcome and low recurrence with early treatment with intravitreal anti-vascular endothelial growth factor in myopic choroidal neovascularization","volume":"237","author":"Moon","year":"2017","journal-title":"Ophthalmologica"},{"key":"R23-20260319","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.preteyeres.2018.10.005","article-title":"Myopic maculopathy: Current status and proposal for a new classification and grading system (ATN)","volume":"69","author":"Ruiz-Medrano","year":"2019","journal-title":"Prog Retin Eye Res"},{"key":"R24-20260319","doi-asserted-by":"crossref","first-page":"10435","DOI":"10.1038\/s41598-022-14287-7","article-title":"Morphological parameters of myopic choroidal neovascularization as predictive factors of anti-VEGF treatment response","volume":"12","author":"Castellino","year":"2022","journal-title":"Sci Rep"},{"key":"R25-20260319","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s00417-023-06271-2","article-title":"Treatment of myopic choroidal neovascularization: A network meta-analysis and review","volume":"262","author":"Glachs","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Journal of Current Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/joco.joco_177_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:24:17Z","timestamp":1787837057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/joco.joco_177_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/joco.joco_177_25","relation":{},"ISSN":["2452-2325"],"issn-type":[{"value":"2452-2325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2025-06-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}